Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer

被引:9
|
作者
He, Yijiao [1 ]
Wang, Yiqin [1 ]
Zhou, Rong [1 ]
Wang, Jianliu [1 ]
机构
[1] Peking Univ, Dept Obstet & Gynecol, Peoples Hosp, Beijing, Peoples R China
关键词
uterine cancer; endometrial neoplasms; endometrial hyperplasia; neoplasm recurrence; local; SPARING MANAGEMENT; ADENOCARCINOMA;
D O I
10.1136/ijgc-2020-001570
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective A number of patients with atypical endometrial hyperplasia and endometrial cancer have not yet given birth when they relapse after achieving complete response with initial fertility-preserving treatment. Often such patients still have a strong desire for fertility preservation; however, there are limited reports in the related literature on the efficacy of fertility-preserving retreatment in patients with relapse. This study intends to evaluate the safety and efficacy of fertility-preserving retreatment in patients with atypical endometrial hyperplasia and endometrial cancer after recurrence following initial fertility-preserving treatment. Methods Data from 110 patients with atypical endometrial hyperplasia and endometrial cancer who received fertility-preserving treatment in the Department of Obstetrics and Gynecology, Peking University People's Hospital (December 2005 to September 2019) were collected, and a retrospective analysis was performed on the clinical characteristics, histopathology results, and outcomes of 25 patients with recurrence. Results 25 patients (9 with atypical endometrial hyperplasia and 16 with endometrial cancer) received fertility-preserving retreatment. After a median treatment duration of 5 months (range 3-18), 21 patients (84%, 21/25) achieved complete response and 4 patients (16%, 4/25) had a partial response. The median follow-up time was 19.5 months (range 8-76), and a total of 8 patients (38.1%, 8/21) relapsed. The time from retreatment to complete response for endometrial cancer was significantly longer than that for atypical endometrial hyperplasia (7.5 vs 3 months; p=0.007). Among the 21 patients who achieved complete response, 12 patients had a desire for fertility, among whom 8 patients had a successful pregnancy (66.7%, 8/12) and 6 patients experienced term birth (1 patient with natural pregnancy and 5 patients with assisted reproductive technology). Six patients (50%, 6/12) delivered 6 full-term babies. Conclusion The response rate is high and obstetrical outcomes are favorable after fertility-preserving retreatment in patients with recurrence of atypical endometrial hyperplasia and endometrial cancer.
引用
收藏
页码:1902 / 1907
页数:6
相关论文
共 50 条
  • [1] Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study
    He, Yijiao
    Wang, Jianliu
    Wang, Yiqin
    Zhou, Rong
    Lu, Qun
    Liu, Guoli
    Tang, Huiru
    Guo, Hongyan
    He, Mian
    Wu, Guizhu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia
    Wang, Yiqin
    Zhou, Rong
    Wang, Haibo
    Liu, Huixin
    Wang, Jianliu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) : 699 - 704
  • [3] Fertility-preserving treatment in young patients with endometrial carcinoma and atypical hyperplasia
    Fujiwara, H.
    Takei, Y.
    Taneichi, A.
    Saga, Y.
    Imai, M.
    Jobo, T.
    Suzuki, M.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S75 - S75
  • [4] The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
    Guan, Jun
    Chen, Xiao-Jun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [5] Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome
    Wang, Lulu
    Luo, Xuezhen
    Wang, Qian
    Lv, Qiaoying
    Wu, Pengfei
    Liu, Wei
    Chen, Xiaojun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (05) : e70
  • [6] OUTCOMES OF REPEATED FERTILITY-PRESERVING HORMONAL THERAPY USING MEDROXYPROGESTERONE ACETATE AMONG 165 YOUNG PATIENTS WITH ENDOMETRIAL CANCER OR ATYPICAL ENDOMETRIAL HYPERPLASIA
    Susumu, N.
    Yamagami, W.
    Ninomiya, T.
    Wada, M.
    Takigawa, A.
    Ichikawa, Y.
    Nomura, H.
    Kataoka, F.
    Hirasawa, A.
    Suzuki, A.
    Tominaga, E.
    Banno, K.
    Aoki, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1596 - 1596
  • [7] Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia
    Takeda, Asuka
    Yamamoto, Yuri
    Tamura, Kou
    Aoki, Hidenori
    Noguchi, Hiroki
    Minato, Saki
    Kamada, Shuhei
    Arakaki, Ryosuke
    Kaji, Takashi
    Iwasa, Takeshi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (04) : 633 - 638
  • [8] Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
    Wu, Pengfei
    Lv, Qiaoying
    Guan, Jun
    Shan, Weiwei
    Chen, Xiaojun
    Zhu, Qin
    Luo, Xuezhen
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 306 (04) : 1135 - 1146
  • [9] Exploring the impact of fertility-preserving treatment on pregnancy: key issues in patients with endometrial cancer and atypical hyperplasia
    Tang, Wei-Zhen
    Liu, Tai-Hang
    HUMAN REPRODUCTION, 2024, 39 (10) : 2364 - 2365
  • [10] Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
    Pengfei Wu
    Qiaoying Lv
    Jun Guan
    Weiwei Shan
    Xiaojun Chen
    Qin Zhu
    Xuezhen Luo
    Archives of Gynecology and Obstetrics, 2022, 306 : 1135 - 1146